mRNA cancer vaccine shows 42% reduction in death and recurrence

mRNA cancer vaccine shows 42% reduction in death and recurrence

Hacker News·3w·Moderna, Merck

Moderna and Merck's personalized mRNA cancer vaccine demonstrated a 42% reduction in death and recurrence for melanoma patients in clinical trials. While this is biotech rather than software, it signals how mRNA technology—once dismissed as speculative—is moving into mainstream medical practice, creating downstream opportunities for indie developers building tools in genomics, clinical data management, and personalized medicine workflows.

Share𝕏Reddit

Related stories